314 related articles for article (PubMed ID: 18246516)
1. Novel inhibitors of human CMV.
Andrei G; De Clercq E; Snoeck R
Curr Opin Investig Drugs; 2008 Feb; 9(2):132-45. PubMed ID: 18246516
[TBL] [Abstract][Full Text] [Related]
2. Human cytomegalovirus DNA replication: antiviral targets and drugs.
Mercorelli B; Sinigalia E; Loregian A; Palù G
Rev Med Virol; 2008; 18(3):177-210. PubMed ID: 18027349
[TBL] [Abstract][Full Text] [Related]
3. Drug targets in cytomegalovirus infection.
Andrei G; De Clercq E; Snoeck R
Infect Disord Drug Targets; 2009 Apr; 9(2):201-22. PubMed ID: 19275707
[TBL] [Abstract][Full Text] [Related]
4. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
5. Antiviral drugs for cytomegalovirus diseases.
Biron KK
Antiviral Res; 2006 Sep; 71(2-3):154-63. PubMed ID: 16765457
[TBL] [Abstract][Full Text] [Related]
6. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.
Kaptein SJ; Efferth T; Leis M; Rechter S; Auerochs S; Kalmer M; Bruggeman CA; Vink C; Stamminger T; Marschall M
Antiviral Res; 2006 Feb; 69(2):60-9. PubMed ID: 16325931
[TBL] [Abstract][Full Text] [Related]
7. Non-nucleoside inhibitors of herpesviruses.
Wathen MW
Rev Med Virol; 2002; 12(3):167-78. PubMed ID: 11987142
[TBL] [Abstract][Full Text] [Related]
8. Antiviral strategies to combat cytomegalovirus infections in transplant recipients.
Lischka P; Zimmermann H
Curr Opin Pharmacol; 2008 Oct; 8(5):541-8. PubMed ID: 18662804
[TBL] [Abstract][Full Text] [Related]
9. Design of translactam HCMV protease inhibitors as potent antivirals.
Borthwick AD
Med Res Rev; 2005 Jul; 25(4):427-52. PubMed ID: 15789440
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection in immunocompetent and immunocompromised individuals--a review.
Vancíková Z; Dvorák P
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):179-87. PubMed ID: 12476798
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
12. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
Eckle T; Jahn G; Hamprecht K
J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
[TBL] [Abstract][Full Text] [Related]
13. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells.
Michaelis M; Ha TA; Doerr HW; Cinatl J
Cardiovasc Res; 2008 Feb; 77(3):544-50. PubMed ID: 18006438
[TBL] [Abstract][Full Text] [Related]
15. Approaches for the generation of new anti-cytomegalovirus agents: identification of protein-protein interaction inhibitors and compounds against the HCMV IE2 protein.
Mercorelli B; Gribaudo G; Palù G; Loregian A
Methods Mol Biol; 2014; 1119():349-63. PubMed ID: 24639231
[TBL] [Abstract][Full Text] [Related]
16. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.
Baldanti F; Gerna G
J Antimicrob Chemother; 2003 Sep; 52(3):324-30. PubMed ID: 12888590
[TBL] [Abstract][Full Text] [Related]
17. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase.
Loregian A; Coen DM
Chem Biol; 2006 Feb; 13(2):191-200. PubMed ID: 16492567
[TBL] [Abstract][Full Text] [Related]
18. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
[TBL] [Abstract][Full Text] [Related]
19. Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of
Jackson JW; Hancock TJ; Dogra P; Patel R; Arav-Boger R; Williams AD; Kennel SJ; Wall JS; Sparer TE
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760613
[TBL] [Abstract][Full Text] [Related]
20. Focus on new drugs in development against human cytomegalovirus.
Emery VC; Hassan-Walker AF
Drugs; 2002; 62(13):1853-8. PubMed ID: 12215056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
